1. Home
  2. RNXT vs UBX Comparison

RNXT vs UBX Comparison

Compare RNXT & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • UBX
  • Stock Information
  • Founded
  • RNXT 2012
  • UBX 2009
  • Country
  • RNXT United States
  • UBX United States
  • Employees
  • RNXT N/A
  • UBX N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • UBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNXT Health Care
  • UBX Health Care
  • Exchange
  • RNXT Nasdaq
  • UBX Nasdaq
  • Market Cap
  • RNXT 31.6M
  • UBX 38.6M
  • IPO Year
  • RNXT 2021
  • UBX 2018
  • Fundamental
  • Price
  • RNXT $1.15
  • UBX $2.10
  • Analyst Decision
  • RNXT Strong Buy
  • UBX Strong Buy
  • Analyst Count
  • RNXT 1
  • UBX 2
  • Target Price
  • RNXT $9.00
  • UBX $7.00
  • AVG Volume (30 Days)
  • RNXT 195.7K
  • UBX 369.6K
  • Earning Date
  • RNXT 03-31-2025
  • UBX 11-04-2024
  • Dividend Yield
  • RNXT N/A
  • UBX N/A
  • EPS Growth
  • RNXT N/A
  • UBX N/A
  • EPS
  • RNXT N/A
  • UBX N/A
  • Revenue
  • RNXT N/A
  • UBX N/A
  • Revenue This Year
  • RNXT N/A
  • UBX N/A
  • Revenue Next Year
  • RNXT N/A
  • UBX $33.62
  • P/E Ratio
  • RNXT N/A
  • UBX N/A
  • Revenue Growth
  • RNXT N/A
  • UBX N/A
  • 52 Week Low
  • RNXT $0.77
  • UBX $0.94
  • 52 Week High
  • RNXT $1.86
  • UBX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 58.08
  • UBX 62.50
  • Support Level
  • RNXT $1.32
  • UBX $2.05
  • Resistance Level
  • RNXT $1.40
  • UBX $2.42
  • Average True Range (ATR)
  • RNXT 0.11
  • UBX 0.31
  • MACD
  • RNXT 0.00
  • UBX -0.01
  • Stochastic Oscillator
  • RNXT 39.47
  • UBX 41.67

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Share on Social Networks: